Amol Akhade, Consultant Medical Oncologist at the Suyog Cancer Clinics, shared a post on LinkedIn:
“DESTINY-Breast09 is one of ASCO 2025’s most anticipated trials! Enhertu + Pertuzumab beat THP in 1L HER2+ MBC with a highly significant PFS benefit as per the press release. But the exact numbers aren’t out yet…
What do you think the results will show for the trial arm- Enhertu plus Pertuzumab – (HR + median PFS)? Think and give me your best guess: Vote now and opine on this survey on X.”
More posts featuring Amol Akhade.